EE05559B1 - IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks - Google Patents

IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks

Info

Publication number
EE05559B1
EE05559B1 EEP200100689A EEP200100689A EE05559B1 EE 05559 B1 EE05559 B1 EE 05559B1 EE P200100689 A EEP200100689 A EE P200100689A EE P200100689 A EEP200100689 A EE P200100689A EE 05559 B1 EE05559 B1 EE 05559B1
Authority
EE
Estonia
Prior art keywords
disorders
prevention
treatment
il6r
kim
Prior art date
Application number
EEP200100689A
Other languages
English (en)
Estonian (et)
Inventor
Revel Michel
Chebath Judith
Pizzi Marina
Spano Pierfranco
Boschert Ursula
Original Assignee
Yeda Research And Development Co. Ltd.
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co. Ltd., Applied Research Systems Ars Holding N.V. filed Critical Yeda Research And Development Co. Ltd.
Publication of EE200100689A publication Critical patent/EE200100689A/xx
Publication of EE05559B1 publication Critical patent/EE05559B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200100689A 1999-06-21 2000-06-21 IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks EE05559B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13058699A IL130586A0 (en) 1999-06-21 1999-06-21 IL6RIL6 chimera for the treatment of demyelinating diseases
PCT/IL2000/000363 WO2000078331A2 (en) 1999-06-21 2000-06-21 Il6ril6 chimera for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
EE200100689A EE200100689A (et) 2003-02-17
EE05559B1 true EE05559B1 (et) 2012-08-15

Family

ID=11072949

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100689A EE05559B1 (et) 1999-06-21 2000-06-21 IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks

Country Status (21)

Country Link
US (1) US7201896B1 (de)
EP (1) EP1185293B1 (de)
JP (1) JP4846148B2 (de)
KR (1) KR100678290B1 (de)
CN (1) CN1164328C (de)
AT (1) ATE306280T1 (de)
AU (1) AU778662B2 (de)
BR (1) BR0011363A (de)
CA (1) CA2374997C (de)
DE (1) DE60023139T2 (de)
DK (1) DK1185293T3 (de)
EA (1) EA004626B1 (de)
EE (1) EE05559B1 (de)
ES (1) ES2250140T3 (de)
HK (1) HK1047549A1 (de)
IL (2) IL130586A0 (de)
MX (1) MXPA02000116A (de)
NO (1) NO329028B1 (de)
UA (1) UA76695C2 (de)
WO (1) WO2000078331A2 (de)
ZA (1) ZA200109488B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5030364B2 (ja) 2000-09-14 2012-09-19 アレス トレーディング ソシエテ アノニム ハンチントン病におけるｉｌ−６ｒ／ｉｌ−６キメラの使用
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
CA2443777A1 (en) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
EP1631662A1 (de) 2003-06-12 2006-03-08 Yeda Research & Development Company, Ltd. Verbesserung der differenzierung von oligodendrozyten
WO2005047492A1 (en) * 2003-11-14 2005-05-26 Olsson Mats J Melanocytes in therapy of neurodegenerative diseases
IL161672A0 (en) * 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
CA3014340A1 (en) * 2016-02-12 2017-08-17 Als Therapy Development Institute Measurement of als progression based on kinetic data
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
JPH1148413A (ja) 1997-08-06 1999-02-23 Dainippon Printing Co Ltd ホルムアルデヒド捕捉壁紙およびその製造方法
JP4859153B2 (ja) * 1999-02-25 2012-01-25 東ソー株式会社 新規神経系細胞分化促進剤

Also Published As

Publication number Publication date
KR100678290B1 (ko) 2007-02-05
EP1185293A2 (de) 2002-03-13
EP1185293B1 (de) 2005-10-12
MXPA02000116A (es) 2003-07-21
ZA200109488B (en) 2002-11-18
DE60023139D1 (de) 2006-02-23
EA200200063A1 (ru) 2002-06-27
ES2250140T3 (es) 2006-04-16
DK1185293T3 (da) 2005-12-27
BR0011363A (pt) 2002-02-26
WO2000078331A3 (en) 2001-07-05
ATE306280T1 (de) 2005-10-15
CA2374997C (en) 2010-04-13
EA004626B1 (ru) 2004-06-24
JP4846148B2 (ja) 2011-12-28
CN1164328C (zh) 2004-09-01
DE60023139T2 (de) 2006-05-04
EE200100689A (et) 2003-02-17
US7201896B1 (en) 2007-04-10
NO20015673D0 (no) 2001-11-20
UA76695C2 (uk) 2006-09-15
IL147188A (en) 2015-09-24
NO329028B1 (no) 2010-08-02
CA2374997A1 (en) 2000-12-28
AU778662B2 (en) 2004-12-16
CN1364088A (zh) 2002-08-14
AU5423100A (en) 2001-01-09
WO2000078331A2 (en) 2000-12-28
IL130586A0 (en) 2000-06-01
KR20020013901A (ko) 2002-02-21
JP2003502382A (ja) 2003-01-21
HK1047549A1 (en) 2003-02-28
NO20015673L (no) 2001-12-17

Similar Documents

Publication Publication Date Title
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
MY124786A (en) Bis-arylsulfones
EE200200214A (et) Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks
EE05559B1 (et) IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks
HK1061661A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
IL162482A (en) Use of the il6 – r / il – 6 chimera in the manufacture of a drug for the treatment of neuronal loss
EE05174B1 (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
BR0206918A (pt) Uso de iloperidona
PT942729E (pt) Utilizacao de antagonistas de receptores nk-1 para tratamento de doencas do stresse
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20160621